Xanthoma Disseminatum Effectively Treated with 2-Chlorodeoxyadenosin (cladribine): a Chinese Case Series and Mini Review of the Literature
Hsiaohan Tuan,Li Kang,Eray Yihui Zhou,Dian Chen,Dehua Liu,Dan Shu,Zhigang Bi,Yi Zhao
DOI: https://doi.org/10.1684/ejd.2019.3629
2019-01-01
European Journal of Dermatology
Abstract:Xanthoma disseminatum (XD) is a rare non-Langerhans cell histiocytosis. Clinical manifestations of XD include cutaneous and mucosal lesions and diabetes insipidus. Recently, good treatment response with 2chlorodeoxyadenosin (cladribine) in several XD patients has been reported [1-3]. In this report, we present three XD cases treated with cladribine in China, including an evaluation of the efficacy and safety of cladribine treatment. It is noteworthy that one of the patients was a child who developed symptoms of XD and was treated with cladribine at a very young age. Our XD patients included three males, and their rashes first developed at the ages of 25, 30 and five. respectively. Yellowish nodules and papules were observed on their face, mucosa, bulbar conjunctiva, perioral region, neck, armpits, and inguinal, genital and perianal region (figure 1A-D, I, K). All patients demonstrated similar histological findings which revealed diffuse foamy cells, multiple Touton giant cells with outspread lymphocytes, plasma cells, and eosinophils (figure 1O, P). Immunohistochemical staining revealed S-100±, CD1a-, CD68++, CD14+++, and FXIIIa +++. All of our cases had severe clinical presentations in which the skin and mucosa were involved extensively, and there were various degrees of infiltration in the pituitary and hypothalamus, accompanied by diabetes insipidus. One patient had hyposmia. One patient suffered from lesions invading his respiratory mucosa, causing voice hoarseness and even life-threatening dyspnoea. A tracheostomy was finally performed to relieve the dyspnoea. Moreover, our paediatric XD patient developed rashes on the bulbar conjunctiva, significantly affecting his vision. The patients were treated with various agents, all of which failed to promote significant improvement. We decided to start cladribine monotherapy (a cycle dose of 0.14 mg/kg/day for five days, with an interval of one month) for our patients and the results were remarkable. The patients started cladribine treatment at the ages of 35, 34 and 12, respectively. After five to nine cycles of cladribine, there was significant resolution of cutaneous and mucosal lesions. After 52-66 months of follow-up, and to date, these patients are still in remission and have not shown any sign of relapse (figure 1 E-H, J, M). Xanthoma disseminatum can be classified into three forms: (1) the rare, self-healing form; (2) the common persistent form; and (3) the very rare progressive form with organ dysfunction or central nervous system involvement [4]. Generally, XD is a benign condition and may achieve spontaneous resolution. Various medications for the treatment of XD, including systemic corticosteroid, A B C D